GlassScriptPhysician profile
Gary A Casaccio
NPI 1063593721
$2,539.42
in general payments reported to CMS, 2019-2025
28 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $272 · 2021: $482 · 2022: $261 · 2023: $90.47 · 2024: $39.92 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $714.84 | 2019 | |
| Abbvie INC. | $244.99 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $202.83 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $143.49 | 2019-2025 | Spravato |
| Lundbeck LLC | $127.82 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.05 | 2020-2022 | |
| Allergan, INC. | $97.51 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $90.19 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $87.34 | 2019-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $81.10 | 2019 | |
| Adlon Therapeutics L.P. | $75.62 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $61.02 | 2019 | |
| Jazz Pharmaceuticals INC. | $57.14 | 2021-2022 | |
| Bausch Health US, LLC | $56.16 | 2019-2021 | |
| Corium, LLC | $55.26 | 2022-2025 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $53.30 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.82 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $42.02 | 2025 | |
| Collegium Pharmaceutical, INC. | $24.52 | 2025 | Jornay Pm |
| Eisai INC. | $23.94 | 2021 | |
| Tris Pharma INC | $23.46 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $21.91 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $21.79 | 2025 | Austedo Xr |
| Rhodes Pharmaceuticals L.P. | $18.97 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.76 | 2019 | |
| Alfasigma USA, INC. | $15.67 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.07 | 2021 | |
| Owp Pharmaceuticals, INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Casaccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.